Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) rose 6% during mid-day trading on Thursday . The company traded as high as $0.4454 and last traded at $0.4451. Approximately 7,000 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 12,085 shares. The stock had previously closed at $0.42.
Defence Therapeutics Stock Performance
The company’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.53.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
See Also
- Five stocks we like better than Defence Therapeutics
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- New gold price target
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
